Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.
about
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery diseaseClassical and novel biomarkers for cardiovascular risk prediction in the United StatesLipoprotein-associated oxidative stress: a new twist to the postprandial hypothesisIdentifying novel biomarkers for cardiovascular disease risk predictionHigh-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammationGDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in menCoronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohortsIncremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality predictionEarly Detection System of Vascular Disease and Its Application ProspectEpidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study.Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany StudyNatriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling.Improved risk stratification in prevention by use of a panel of selected circulating microRNAs.Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk.Biomarkers and cardiovascular risk assessment for primary prevention: an update.Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study.B-type natriuretic peptide-guided therapy for perioperative medicine?BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countriesGenetic markers enhance coronary risk prediction in men: the MORGAM prospective cohortsAssessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction.Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of womenNT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus StudyBiobanking in atherosclerotic disease, opportunities and pitfalls.Comparison of three troponins as predictors of future cardiovascular events--prospective results from the FINRISK and BiomaCaRE studiesEvaluating the clinical utility of a biomarker: a review of methods for estimating health impactMetabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts.Pooled exposure assessment for matched case-control studiesThe high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population.Evaluating the incremental value of new biomarkers with integrated discrimination improvement.High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS).Determination of phospholipase activity of PAF acetylhydrolaseAtherosclerosis: from biology to pharmacological treatment.
P2860
Q24615584-AA4A0D94-95EA-4426-A301-C22435CBF872Q26824026-CF6051CE-8741-4BD4-8A78-5638F6D8E927Q26828643-2862E2F3-CD27-43DF-8BFF-DF6C9807CA7FQ26865722-95C29B3F-FCFA-4296-9230-E04CAB7068FCQ28480869-F26AD6B8-5F46-4B85-85FB-3A4601272D97Q28535575-90E6E4D3-E3F5-499E-99AC-57FB4765188DQ28686330-F3A9ECF9-6D46-4D32-B093-550A94946F80Q28731264-91C2F4C8-CE28-4B83-A47F-BE9F9FA5BEF5Q30239836-35A2DC4A-277A-4120-9C66-43283E540CB8Q30251632-8B0CCCA3-2DED-4A76-B144-9457C22AB89FQ30276065-9E6C2FCD-7CB0-4955-A9D5-2C38BDA48411Q30316351-38E05BED-1E73-4341-8B18-23360F3A4DE1Q31126960-F33FDCC5-BE12-4407-9724-BDB36EBF94B0Q33551467-C8D03FC9-ADAB-4E9A-9638-035A67635464Q33797033-C5E50742-B448-4A53-9B2B-3AA466C0DED3Q33866958-D0D1AC12-C2FB-4502-99B1-D849AFF30B3EQ33873812-8FB0B3BA-7CC8-47CC-ADAC-6C7E6C23F264Q33927398-D92DA51E-DF9E-4107-8176-C1C14FF81BC4Q33932928-18ABE424-E2C6-40C4-8994-2C0A70ADCE6CQ33972551-621DBC8E-7053-433D-9DDE-DD998BD53EC7Q34150309-03317DF9-0BF9-4C40-8C26-41C09E9C1ACAQ34304406-1AE5C412-1855-48E5-BF88-2965D761B404Q34340697-79772832-24A3-49F3-8122-1839A683A7CAQ34358091-50244DBC-B4FE-4C89-960A-9ED8B2DD4EDFQ34691058-B93E4BD0-B26F-4A2B-A614-EBF6F8729512Q34768805-5AD9628A-CB03-452C-9D9E-C0FB8F4BABBFQ34954819-DD0505A2-342B-4589-A617-A2E579C4DD6AQ35054042-E0A99AF9-D38D-4B48-9921-BFE6CEA99278Q35092154-BD97548A-1AEE-4855-B0FE-15873A277289Q35110759-18B7EFF7-B879-4710-9623-C6F6696EE405Q35112353-D685B7AE-73F6-4169-B61C-E4DFD36522D7Q35152158-4D83ABD2-2EA0-4230-BD4B-DC006104EE6CQ35177299-99718DEC-0AFC-471C-9609-320BD21E7982Q35190823-8BB87EC3-9FBF-4C43-B9B5-0AD90769AD06Q35450631-9C6FF8D6-95FC-452F-9094-57B5BAA8B918Q35648924-372DD6FE-8DB4-4E55-9EFC-A863C12A283BQ36100361-80286558-A263-4793-AA1F-C7D6060F6A11Q36181627-7DE5098F-F633-4206-9359-8BBA846C9F44Q36240691-082D36B2-47FD-4148-B9DB-CE66282272A8Q36313684-39F8B028-1B42-4BC4-8A0D-A14A513A3B17
P2860
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Contribution of 30 biomarkers ...... ph (MORGAM) biomarker project.
@en
type
label
Contribution of 30 biomarkers ...... ph (MORGAM) biomarker project.
@en
prefLabel
Contribution of 30 biomarkers ...... ph (MORGAM) biomarker project.
@en
P2093
P50
P1433
P1476
Contribution of 30 biomarkers ...... ph (MORGAM) biomarker project.
@en
P2093
Alun Evans
Hugh Tunstall-Pedoe
John Yarnell
Karl J Lackner
Laurence Tiret
MORGAM Project
Olli Saarela
Philipp S Wild
Renate B Schnabel
P304
P356
10.1161/CIRCULATIONAHA.109.901413
P407
P577
2010-05-24T00:00:00Z